SCHEMBL5863322

SCHEMBL5863322

CCOC(=O)c1ccn2nc(C)[nH]c(=O)c12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
NR1H2 P55055 1/20 0.44
KDM4E B2RXH2 4/20 0.44
HPGD P15428 1/20 0.44
RAB9A P51151 1/20 0.44
HIF1A Q16665 1/20 0.44
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 3/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SPR P35270 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16646776 0.78 NR1H2 (0.66) ALDH1A1MAPTL3MBTL1LMNANR1H2
SCHEMBL18397505 0.73 KMT2A (0.43) ALDH1A1KDM4EHPGDRAB9AKMT2A
SCHEMBL12283713 0.71 AAK1 (0.48) ALDH1A1HPGDRAB9ATSHRSMN1; SMN2
SCHEMBL16646777 0.70 EGFR (0.46) ALDH1A1HPGDRAB9ATSHRSMN1; SMN2
SCHEMBL25345519 0.70 NR1H2 (0.50) ALDH1A1MAPTL3MBTL1LMNANR1H2
SCHEMBL5863360 0.70 PARP1 (0.38) SMN1; SMN2
SCHEMBL5863407 0.69 TSHR (0.52) ALDH1A1L3MBTL1LMNAKDM4EHPGD
SCHEMBL1014580 0.69 KDM4E (0.58) ALDH1A1MAPTL3MBTL1LMNAKDM4E
SCHEMBL27153476 0.68 L3MBTL1 (0.49) ALDH1A1MAPTL3MBTL1LMNANR1H2
SCHEMBL404918 0.68 PLAT (0.53) ALDH1A1MAPTL3MBTL1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030118-B2 Pyrrolotriazinone compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US disclosed
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents BRISTOL-MYERS SQUIBB COMPANY 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents CCNB1, NUMA1, CCNA1 ALDH1A1 1027/4885MAPT 2689/4885L3MBTL1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.